{"nct_id":"NCT05245071","title":"Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA","status":"TERMINATED","status_verified_date":"2025-08","start_date":"2022-06-01","start_date_type":"ACTUAL","primary_completion_date":"2024-03-06","primary_completion_date_type":"ACTUAL","completion_date":"2024-11-20","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["SNY"]}